Catecholamine stimulation is associated with impaired myocardial O2 utilization in heart failure

Cardiovascular Research

Volumn 53, Issue 2, 2002, Pages 392-404

  Nikolaidis, Lazaros A ^a   Hentosz, Teresa ^a   Doverspike, Aaron ^a   Huerbin, Rhonda ^a   Stolarski, Carol ^a   Shen, You Tang ^b   Shannon, Richard P ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adrenergic (ant)agonists; Cardiomyopathy; Energy metabolism; Heart failure; Hemodynamics; Oxygen consumption

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; DOBUTAMINE; FATTY ACID; ISOPRENALINE; METOPROLOL; NORADRENALIN; OXYGEN; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DESENSITIZATION; DISEASE ASSOCIATION; DOG; DRUG EFFECT; FATTY ACID OXIDATION; FEMALE; GLYCOLYSIS; HEART CONTRACTION; HEART DILATATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART PACING; HEART RATE; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY QUOTIENT;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; CARDIOMYOPATHY, DILATED; CATECHOLAMINES; DOBUTAMINE; DOGS; FEMALE; ISOPROTERENOL; MALE; METOPROLOL; MODELS, ANIMAL; MYOCARDIAL CONTRACTION; MYOCARDIUM; NOREPINEPHRINE; OXYGEN CONSUMPTION; PHENYLEPHRINE; STIMULATION, CHEMICAL;

EID: 0036162364     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00490-4     Document Type: Article

References (47)

1. Is the failing heart energy depleted?
2. Is cardiac failure a consequence of decreased energy reserve?
3. Energy metabolism of the heart: From basic concepts to clinical applications
4. Dissociation between regional dysfunction and beta-adrenergic receptor signaling in heart failure
5. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and sub-sensitivity to agonist response
6. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy
7. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
8. Meta-analysis of effect of β-blockade on mortality in NYHA class IV chronic heart failure patients
9. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial
10. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
11. Intermittent dobutamine in ambulatory outpatients with chronic heart failure
12. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group
13. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure
14. Xamoterol in severe heart failure
15. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy
16. Cardiac adrenergic receptor effects of carvedilol
17. The β-blocking agents metoprolol and carvedilol affect cardiac adrenergic drive differently in subjects with heart failure from idiopathic dilated cardiomyopathy
18. Comparative hemodynamic, left ventricular functional and anti-adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
19. Prospective randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure
20. Alterations in myocardial contractility in conscious dogs with dilated cardiomyopathy
21. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure
22. Chronic elevation of norepinephrine in conscious dogs produces hypertrophy with no loss of left ventricular reserve
23. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure
24. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog
25. Depressed β-adrenergic receptor and endothelium-mediated vasodilation in conscious dogs with heart failure
26. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human heart
27. Beta-adrenergic receptor desensitization during development of canine pacing-induced heart failure
28. New insights into the role of enhanced adrenergic receptor-effector coupling in the heart
29. Mechanisms and models in heart failure: A combinatorial approach
30. Glucose for the heart
31. β-Adrenergic receptor blockade in chronic heart failure
32. Changes in myocardial and vascular receptors in heart failure
33. Enhanced myocardial relaxation in vivo in transgenic mice overexpressing the β-2-adrenergic receptor is associated with reduced phospholamban protein
34. Opposing effects of β-1 and β-2 adrenergic receptors on cardiac myocyte apoptosis
35. Catecholamines, cardiac β-adrenergic receptors and heart failure
36. β-Adrenergic receptor signaling: An acute compensatory adjustment: Inappropriate for the chronic stress of heart failure
37. Cellular mechanisms in congestive heart failure
38. Myocardial metabolism
39. Single-site and bi-ventricular pacing therapy in patients with dilated cardiomyopathy and intraventricular conduction delay achieves systolic benefit at reduced energetic cost
40. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using C-11 acetate kinetics in patients with dilated cardiomyopathy
41. Myocardial efficiency during levosimendan infusion in congestive heart failure
42. Dobutamine enhances both contractile function and energy reserves in hypoperfused canine right ventricle
43. Gas transport by the blood
44. Oxygen transport: Model and reality
45. In vivo β-3 adrenergic stimulation of human thermogenesis and lipid use
46. Differences in β-3 adrenergic receptors cardiovascular regulation in conscious primates, rats and dogs